Abstract P48 Figure 1 Decision tree classifier using VAS for identification of an exacerbation of COPD

95% CI for VAS cough, VAS dyspnoea, sputum production and purulence was 26 mm (20–32); 25 mm (19–30); 25 mm (19–31) and 25 mm (18–31) respectively.

The J48 classifier decision tree had the most predictive accuracy (80%) of identifying an exacerbation (Figure 1), based on VAS and score.

Conclusion Unbiased mathematical modelling of the VAS may be useful in determining a true exacerbation event. The addition of characterisation based upon VAS may enhance the ability to identify exacerbations.

P49 HIGHER SERVICE USE AMONGST PATIENTS WITH ADVANCED COPD AND PSYCHOLOGICAL CO-MORBIDITIES: ASSOCIATIONS WITH QUALITY OF LIFE, CO-MORBIDITIES AND EXACERBATIONS

¹AC Gardener, ¹M Farquhar, ¹H Holt Butcher, ¹C Moore, ²G Ewing, ³P White, ⁴S Howson, ⁵R Mahadeva, ⁵S Booth, ⁶P Burge, ¹S Mendonca. ¹Primary Care Unit, University of Cambridge, Cambridge, UK; ²Centre for Family Research, University of Cambridge, Cambridge, UK; ³King's College London, London, UK; ⁴Cambridgeshire and Peterborough NHS Foundation Trust, UK; ⁵Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; ⁶RAND Europe, Cambridge, UK

10.1136/thoraxjnl-2015-207770.186

Background There is a high prevalence of anxiety and depression among people with Chronic Obstructive Pulmonary Disease (COPD). Anxiety and depression are frequently associated with increased service use, particularly hospital admission; other demographic and health variables are also known to be significant in this relationship. However, less is known about the nature of these relationships when COPD is advanced. The aim of this study was to identify the relationship between anxiety and depression and service use in patients with advanced COPD, together with the role of key demographic and health variables.

Methods A well-characterised population-based cohort of patients with advanced COPD completed the Hospital Anxiety and Depression Scale (HADS) and reported hospital and community service use and experiences. Patient demographics and health variables were also collected. Univariate analyses of associations between service use and anxiety, depression, health

variables and demographics were carried out using data collected over a three month period.

Results 235 patients recruited: mean age 71.6 (SD 10.3); 61% male; mean MMRC dyspnea scale 3.68 (SD 1.040); mean CAT score 23.4 9 (SD7.5). Anxiety and depression scores (HADS) were higher than population norms. Univariate associations (Table 1) were identified between anxiety and contact with a GP ($p = 0.021$) and depression and in-patient admission ($p = 0.017$). Other variables crudely associated with GP service use, were the number of exacerbations managed at home ($p = 0.006$), co-morbidities ($p = 0.014$) and the CRQ dyspnea, physical and emotional domains ($p = 0.014$, 0.011 and 0.032 respectively). Crude associations were also found between inpatient admissions and the number of exacerbations at home ($p = 0.034$) and the CRQ dyspnea domain ($p = 0.014$).

Abstract P49 Table 1 Univariate associations between patient factors and service use (in-patient admission and GP consultations) during a three month period

	In-Patient admission			Contact with GP		
	Y	N	Sig	Y	N	Sig
Contact in last 3 months?						
Anxiety%						
No/Mild	10.2%	89.8%	0.104	65.6%	34.4%	0.021
Probable	18.3%	81.7%		81.7%	18.3%	
Depression%						
No/Mild	10.5%	89.5%	0.017	68.1%	31.9%	0.084
Probable	26.9%	73.1%		84.6%	15.4%	
Other Variables (median and IQR)						
Exacerbations at home (No.)	2 (0–4)	1 (0–2)	0.034	2 (0–4)	1 (0–2)	0.006
CRQ: Dyspnea	3 (2–3.9)	3.5 (2.4–4.4)	0.014	3 (2–3.9)	3.5 (2.5–4.4)	0.014
CRQ: Physical	—	—	—	3 (2–4)	3.6 (2.5–4.6)	0.011
CRQ: Emotional	—	—	—	4.4 (3.5–5.2)	4.9 (3.8–5)	0.092
Co-morbidities	—	—	—	4 (3–6)	3 (2–4.8)	0.012

Conclusion Patients with advanced COPD and co-morbid anxiety were more likely to have had contact with their GP. Those with co-morbid depression were more likely to have had an inpatient admission. Variables associated with these relationships may include health related quality of life, co-morbidities and exacerbations managed at home. On-going work will validate these conclusions by analysing data collected over an 18 month period. Supportive interventions targeting patients with comorbid anxiety and depression may ameliorate the effects of psychological morbidity and reduce admissions.

P50 PREDICTING READMISSION FOLLOWING EXACERBATION OF COPD USING A NON-CONTACT SENSOR – A PROOF OF CONCEPT STUDY

¹P Minnis, ²R O'Meara, ³H Kane, ³A Zaffaroni, ³F O'Dea, ³J Britton, ²B Caulfield, ¹SC Donnelly. ¹Department of Medicine, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland; ²Insight Centre for Data Analytics, UCD, Dublin, Ireland; ³ResMed Nexus UCD, Dublin, Ireland

10.1136/thoraxjnl-2015-207770.187

Introduction and objectives Chronic Obstructive Pulmonary Disease (COPD) is the second most common cause of emergency admission to hospital in the UK. Following an exacerbation there is a high risk of recurrence. Early identification and prompt treatment of exacerbations have been shown to reduce risk of hospital admission.¹ Respiratory rate changes during an episode of exacerbation and may serve as the warning signal of developing exacerbation. We aimed to determine whether a non-contact bedside sensor (SleepMinder TM) recording Nocturnal Respiratory Rate (NRR) could detect exacerbations in patients with COPD following hospital discharge.

Methods Patients were enrolled following a hospital admission for an exacerbation of their underlying COPD. They were followed prospectively for 12 weeks and monitored by SleepMinder TM (ResMed) technology recording NRR. Demographics and clinical details were extracted from medical records. A research nurse contacted each participant weekly and recorded CAT scores and any healthcare contacts.

Results 15 patients completed the study period and recorded >75% of study data. Of these 8 patients had further exacerbations. Median time post discharge for an exacerbation was 56.5 days (IQR 41–67). There were no differences in baseline demographics between those who had an exacerbation and those that did not however there was a trend towards increased BMI, baseline CAT score and length of stay. Of the 8 patients who had an exacerbation a clear signal in NRR could be identified, by visual inspection, in 5 (62.5%) around the time of recorded health care contact. The average time from a signal to health care contact was 6.6 days indicating a window of opportunity for intervention. There was no significant trend between change of CAT score and change of NRR indicating patients may be unaware of impending exacerbation (p value 0.243).

Conclusions SleepMinder TM technology assessing nocturnal respiratory rate may have use in a real time clinician led connected health setting to trigger early intervention and prevent readmission following discharge.

REFERENCE

- 1 Wilkinson TM, Donaldson GC, Hurst JR, *et al.* Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2004;**169**:1298–303

P51 ADVANCING QUALITY (AQ) REDUCING VARIATION AND IMPROVING QUALITY AND OUTCOMES FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE NORTH WEST OF ENGLAND

¹J Roberts, ²D Szwandt, ²S Hammond. ¹Salford Royal Foundation Trust, Salford, Manchester; ²AQuA, Sale, Manchester

10.1136/thoraxjnl-2015-207770.188

Introduction and objectives COPD patients in the North West of England die 15 years earlier than expected.

Advancing Quality is a programme of work where a common approach supports quality improvement that focuses on clinical pathways.

Methods A regional clinical expert group agreed the AQ COPD evidence based measures (clinical interventions) in February 2013.

The AQ COPD clinical interventions are:

Within 4 Hours Hospital Arrival: Oxygen - Bronchodilator - Corticosteroid - Antibiotic Therapy.

During Hospital Admission: Smoking Cessation - Pulmonary Rehab - Inhaler Technique - Written Self-Management Plan - Spirometry - Home Oxygen - Appropriate End of Life Care – follow up.

Following an initial pilot, AQ COPD went live in September 2014. AQ is a proven approach to improve quality, providing standardisation and transparency for providers and commissioners.

Results Trusts aim to deliver all the interventions that the patient is eligible for, this is known as the Appropriate Care score (ACS). More patients are receiving “perfect care” with AQ, (see Figure 1).

Abstract P51 Figure 1 Advancing Quality (AQ) reducing variation and improving quality and outcomes for patients with Chronic Obstructive Pulmonary Disease (COPD) in the North West of England

Trusts participating in AQ had a mean LOS of 4.7 days compared to 5.7 days for non-participating trusts and average bed days for patients re-admitted in participating trust was 5.5 days compared to 11.8 days in non-participating trusts. Trusts participating saw their readmission rate fall to 20.1% over the period (a reduction of 9%).

Conclusion A regional standardised approach, focused on a small but significant set of clinical interventions, can have a significant impact on improving patient care and outcomes.